MS in Belgium: Key Statistics & Facts from Atlas of MS

The latest edition of the Atlas of MS shows there are 2.92.9
millionmillion people living with multiple sclerosis around the world.
The Atlas of MS is a powerful advocacy tool for MS organisations and
advocates to drive policy changes that can remove obstacles for
people with MS and their families in their country. The data is a key
way of shining a spotlight on MS to increase awareness and
understanding around the world.
Who is aected? BELGIUM
32
years is the global average age of an MS
diagnosis. Data is not available on the age of
diagnosis for this country.
67%
of people with MS are women.
Number of people with MS? BELGIUM
12,000
people are living with MS. This equates to 1 in
every 1,000 people.
32,000
people under 18 years are diagnosed with MS in
the 55 countries that were able to provide
pediatric data. Information on pediatric MS is
not available for this country.
Diagnosis of MS? BELGIUM
450
new people are diagnosed each year. That's 38
diagnosed every month.
85%
of people across the globe are initially
diagnosed with relapsing-remiing MS. 12%
have progressive MS at diagnosis and for 3% the
type is unknown at diagnosis. Data on the type
of MS people have at initial diagnosis is not
available for this country.
MS neurologists BELGIUM
180
neurologists who specialise in MS. This means
there is 1 MS neurologist for every 67 people
with MS
MS nurses BELGIUM
45
nurses who specialise in MS. This means there
is 1 MS nurse for every 267 people with MS
FactsheetFactsheet
Belgium
Key statistics and data collected from MSIF's Atlas of MS
www.atlasofms.org
www.atlasofms.org/downloadreport
www.atlasofms.org/faqs
www.atlasofms.org/powerfultoolforchange

FactsheetFactsheet
Belgium
Key statistics and data collected from MSIF's Atlas of MS
www.atlasofms.org
www.atlasofms.org/downloadreport
www.atlasofms.org/faqs
www.atlasofms.org/powerfultoolforchange

Disease modifying therapies used to treat MS BELGIUM
In the Atlas of MS we categorise on-label DMTs into three classes: moderate ecacy, good ecacy and high
ecacy. Countries should aim to have access to a range of DMTs so that people with MS have options to suit
their disease course and individual circumstances.
On-label DMTs used by ecacy category
High ecacy Good ecacy Moderate ecacy
Alemtuzumab
Natalizumab
Ocrelizumab
Ofatumumab
Cladribine (oral)
Dimethyl fumarate
Diroximel fumarate
Fingolimod
Monomethyl fumarate
Ozanimod
Ponesimod
Siponimod
Glatiramer acetate
Interferon-beta 1a
Interferon-beta 1b
Peginterferon-beta 1a
Teriunomide
O-label DMTs used
Cyclophosphamide Mitoxantrone
DMT used in this country DMT not used in this country
DMTs that have been licensed specically for MS are referred to as 'on-label'. Please note on and o-label here refers to the
regulatory status in the majority of countries.
FactsheetFactsheet
Belgium
Key statistics and data collected from MSIF's Atlas of MS
www.atlasofms.org
www.atlasofms.org/downloadreport
www.atlasofms.org/faqs
www.atlasofms.org/powerfultoolforchange